Pregnancy Failure and Heritable Thrombophilia

Seminars in Hematology

Volumn 44, Issue 2, 2007, Pages 93-97

  Middeldorp, Saskia ^a  

^a Department of Endocrinology and General Internal Medicine   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; FETUS DEATH; FETUS WASTAGE; HUMAN; HYPERCOAGULABILITY; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MONOTHERAPY; PREECLAMPSIA; PREGNANCY DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; THROMBOPHILIA;

ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION DISORDERS, INHERITED; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIALS; THROMBOPHILIA;

EID: 34047263027     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.01.005     Document Type: Article

References (53)

1. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh 13 (1965) 516-530
2. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., and Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68 (1981) 1370-1373
3. Comp P.C., and Esmon C.T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 311 (1984) 1525-1528
4. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Rond, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
5. Dahlback B., Carlsson M., and Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90 (1993) 1004-1008
6. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
7. Falcon C.R., Cattaneo M., Panzeri D., Martinelli I., and Mannucci P.M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14 (1994) 1080-1083
8. den Heijer M., Rosendaal F.R., Blom H.J., Gerrits W.B., and Bos G.M. Hyperhomocysteinemia and venous thrombosis: A meta-analysis. Thromb Haemost 80 (1998) 874-877
9. Rosenberg I.H., and Mulrow C.D. Trials that matter: Should we routinely measure homocysteine levels and "treat" mild hyperhomocysteinemia?. Ann Intern Med 145 (2006) 226-227
10. den Heijer R.M., Willems H.P., Blom H.J., Gerrits W.B., Cattaneo M., Eichinger S., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism. A randomized, placebo-controlled, double blind trial. Blood 109 (2007) 139-144
11. Van de Poel M.H., Coppens M., Middeldorp S., Hamulyak K., Veeger N.J., Prins M.H., et al. Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia. Results from a retrospective family cohort study. J Thromb Haemost 3 suppl 1 (2005) P0481
12. Ray J.G., Shmorgun D., and Chan W.S. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: Meta-analysis of 31 studies. Pathophysiol Haemost Thromb 32 (2002) 51-58
13. Koster T., Blann A.D., Briet E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345 (1995) 152-155
14. Kamphuisen P.W., Houwing-Duistermaat J., Van Houwelingen H.C., Eikenboom J.C.J., Bertina R.M., and Rosendaal F.R. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 79 (1998) 323-327
15. Bank I., Libourel E.J., Middeldorp S., Hamulyak K., van Pampus E.C.M., Koopman M.M.W., et al. Elevated levels of FVIII:c within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 3 (2005) 79-84
16. Kamphuisen P.W., Lensen R., Houwing-Duistermaat J.J., Eikenboom J.C., Harvey M., Bertina R.M., et al. Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. Br J Haematol 109 (2000) 519-522
17. Farquharson R.G., Jauniaux E., and Exalto N. Updated and revised nomenclature for description of early pregnancy events. Hum Reprod 20 (2005) 3008-3011
18. Rai R., and Regan L. Recurrent miscarriage. Lancet 368 (2006) 601-611
19. Goddijn M., and Leschot N.J. Genetic aspects of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol 14 (2000) 855-865
20. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
21. Sanson B.J., Friederich P.W., Simioni P., Zanardi S., Huisman M.V., Girolami, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 75 (1996) 387-388
22. Preston F.E., Rosendaal F.R., Walker I.D., Briet E., Berntorp E., Conard J., et al. Increased fetal loss in women with heritable thrombophilia. Lancet 348 (1996) 913-916
23. Meinardi J.R., Middeldorp S., de Kam P.J., Koopman M.M.W., van Pampus E.C.M., Hamulyak K., et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 130 (1999) 736-739
24. Rey E., Kahn S.R., David M., and Shrier I. Thrombophilic disorders and fetal loss: A meta-analysis. Lancet 361 (2003) 901-908
25. Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.D.O., et al. Thrombophilia in pregnancy: A systematic review. Br J Haematol 132 (2006) 171-196
26. Morrison E.R., Miedzybrodzka Z.H., Campbell D.M., Haites N.E., Wilson B.J., Watson M.S., et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: Results from a large population-based study and systematic review. Thromb Haemost 87 (2002) 779-785
27. Sebire N.J., Regan L., and Rai R. Biology and pathology of the placenta in relation to antiphospholipid antibody-associated pregnancy failure. Lupus 11 (2002) 641-643
28. Quenby S., Mountfield S., Cartwright J.E., Whitley G.S., Chamley L., and Vince G. Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril 83 (2005) 691-698
29. Bose P., Black S., Kadyrov M., Weissenborn U., Neulen J., Regan L., et al. Heparin and aspirin attenuate placental apoptosis in vitro: Implications for early pregnancy failure. Am J Obstet Gynecol 192 (2005) 23-30
30. Isermann B., Sood R., Pawlinski R., Zogg M., Kalloway S., Degen J.L., et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 9 (2003) 331-337
31. Rai R., Cohen H., Dave M., and Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314 (1997) 253-257
32. Farquharson R.G., Quenby S., and Greaves M. Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment. Obstet Gynecol 100 (2002) 408-413
33. Noble L.S., Kutteh W.H., Lashey N., Franklin R.D., and Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: Prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 83 (2005) 684-690
34. Empson M., Lassere M., Craig J.C., and Scott J.R. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. The Cochrane Database of Systematic Reviews 2 (2005)
35. Pattison N.S. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid antibody syndrome?. A randomized controlled trial. Am J Obstet Gynecol 183 (2000) 1008-1101
36. Bates S., Greer I.A., Hirsh J., and Ginsberg J.S. Use of antithrombotic agents during pregnancy. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 suppl (2004) 627S-644S
37. Pabinger I., and Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Haemost 3 (2005) 1603-1010
38. Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications-Yes. J Thromb Haemost 1 (2003) 2070-2072
39. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications-No. J Thromb Haemost 1 (2003) 2073-2074
40. Rai R., Backos M., Elgaddal S., Shlebak A., and Regan L. Factor V Leiden and recurrent miscarriage-Prospective outcome of untreated pregnancies. Hum Reprod 17 (2002) 442-445
41. Lindqvist P.G., and Merlo J. The natural course of women with recurrent fetal loss. J Thromb Haemost 4 (2006) 896-897
42. Coppens M., Folkeringa N., Teune M., Hamulyak K., van der Meer J., Prins M.H., et al. Natural course of the subsequent pregnancy after a single loss in women with and without the factor V Leiden or prothrombin 20210A mutations. Blood suppl (2006)
43. Gris J.C., Mercier E., Quere I., Lavigne-Lissalde G., Cochery-Nouvellon E., Hoffet M., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103 (2004) 3695-3699
44. Rodger M. Important publication missing key information. Blood 104 (2004) 3413
45. Gris J.C., Quere I., Dauzat M., and Mares P. Response: Thromboprophylaxis for first fetal loss. Blood 104 (2004) 3413-3414
46. DiNisio M., Peters L.W., and Middeldorp S. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. The Cochrane Database of Systematic Reviews 2 (2005)
47. Brenner B., Hoffman R., Carp H., Dulitzky M., Younis J., and LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: The LIVE-ENOX study. J Thromb Haemost 3 (2005) 227-229
48. Lindqvist P.G., and Merlo J. Low molecular weight heparin for repeated pregnancy loss-Is it based on solid evidence?. J Thromb Haemost 3 (2005) 221-223
49. Middeldorp S. The use of LMWH in pregnancies at risk: New evidence or perception?. J Thromb Haemost 3 (2005) 788-789
50. Dolitzky M., Inbal A., Segal Y., Weiss A., Brenner B., and Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 86 (2006) 362-366
51. Bank I., Libourel E.J., Middeldorp S., van Pampus E.C.M., Koopman M.M.W., Hamulyak K., et al. Prothrombin 20210A mutation: A mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 164 (2004) 1932-1937
52. Middeldorp S., van der Poel M.H., Bank I., Hamulyak K., Libourel E.J., Koopman M.M.W., et al. Unselected women with elevated levels of factor VIII:c or homocysteine are not at increased risk for obstetric complications. Thromb Haemost 92 (2004) 787-790
53. Nelen W.L., Blom H.J., Steegers E.A., den Heijer M., and Eskes T.K. Hyperhomocysteinemia and recurrent early pregnancy loss: A meta-analysis. Fertil Steril 74 (2000) 1196-1199